{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:34:23Z","timestamp":1740126863636,"version":"3.37.3"},"reference-count":80,"publisher":"Georg Thieme Verlag KG","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Monbl Augenheilkd"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background Noninfectious posterior and panuveitis may exhibit a chronic relapsing clinical course and are challenging to treat. Most affected patients are continuously treated with systemic immunosuppressive therapy, which is potentially associated with significant adverse side effects.<\/jats:p><jats:p>\n          Methods A cohort of 18 patients presenting with severe noninfectious posterior or panuveitis were evaluated with respect to the clinical course of the disease, with particular focus on best-corrected visual acuity (BCVA), treatment duration, remission rates, reported negative side effects, and the necessity for switching medication.<\/jats:p><jats:p>\n          Results The mean follow-up was 27.8 months. Although BCVA improved significantly, complete or partial remission was observed in only 66.7% of patients. Of the patients, 72.2% underwent a change in medical treatment due to either adverse events or inefficacy of medication.<\/jats:p><jats:p>\n          Conclusion Despite new immunosuppressive therapies, effective treatment of severe noninfectious posterior and panuveitis remains a major challenge. We discuss the urgent need for novel treatment strategies in order to prevent systemic adverse effects, and to improve visual outcome and quality of life.<\/jats:p>","DOI":"10.1055\/a-2074-9102","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T17:50:41Z","timestamp":1690393841000},"page":"1349-1360","source":"Crossref","is-referenced-by-count":0,"title":["The Challenge of Treating the Severest Forms of Chronic Noninfectious Posterior and Panuveitis"],"prefix":"10.1055","volume":"241","author":[{"given":"Christoph","family":"Spartalis","sequence":"additional","affiliation":[{"name":"Ophthalmology, Hanusch Hospital, Wien, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"St\u00fcbiger","sequence":"additional","affiliation":[{"name":"Ophthalmology, University Hospital Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin S.","family":"Spitzer","sequence":"additional","affiliation":[{"name":"Ophthalmology, University Hospital Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udo","family":"Bartsch","sequence":"additional","affiliation":[{"name":"Ophthalmology, University Hospital Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1840-0478","authenticated-orcid":false,"given":"Yevgeniya","family":"Atiskova","sequence":"additional","affiliation":[{"name":"Ophthalmology, University Hospital Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3109\/09273948.2014.1002567","article-title":"Spectrum of Uveitis in A German Tertiary Center: Review of 474 Consecutive Patients","volume":"23","author":"R S Grajewski","year":"2015","journal-title":"Ocul Immunol Inflamm"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"D A Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1136\/bjo.2003.037226","article-title":"Degree, duration, and causes of visual loss in uveitis","volume":"88","author":"O M Durrani","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.5301\/ejo.5000278","article-title":"Review on the worldwide epidemiology of uveitis","volume":"23","author":"E Miserocchi","year":"2013","journal-title":"Eur J Ophthalmol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaophthalmol.2016.3229","article-title":"Prevalence of Noninfectious Uveitis in the United States: A Claims-Based Analysis","volume":"134","author":"J E Thorne","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1517\/14712598.2014.956074","article-title":"New pharmacotherapy options for noninfectious posterior uveitis","volume":"14","author":"U Pleyer","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.18053\/jctres.201502.003","article-title":"Diagnosis and treatment of uveitis; not restricted to the ophthalmologist","volume":"2015","author":"J AM van Laar","year":"2015","journal-title":"J Clin Transl Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3109\/09273948.2011.646382","article-title":"High-dose intravenous corticosteroids for ocular inflammatory diseases","volume":"20","author":"L D Charkoudian","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1517\/14740338.2015.1044969","article-title":"Treatment of severe non-infectious uveitis in high-risk conditions (Part I): pregnancy and malignancies, management and safety issues","volume":"14","author":"M Cordero-Coma","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/ceo.13511","article-title":"New therapies in development for the management of non-infectious uveitis: A review","volume":"47","author":"M Hassan","year":"2019","journal-title":"Clin Exp Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"D A Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"102481","DOI":"10.1016\/j.jaut.2020.102481","article-title":"Comparison of conventional immunosuppressive drugs versus anti-TNF-alpha agents in non-infectious non-anterior uveitis","volume":"113","author":"M Leclercq","year":"2020","journal-title":"J Autoimmun"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2174\/1566524015666150731103847","article-title":"Therapies in Development for Non-Infectious Uveitis","volume":"15","author":"M A Sadiq","year":"2015","journal-title":"Curr Mol Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s10792-018-0984-1","article-title":"Optimising drug therapy for non-infectious uveitis","volume":"39","author":"M A Shahab","year":"2019","journal-title":"Int Ophthalmol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/08820538.2016.1228402","article-title":"A Review of the Course and Treatment of Non-Infectious Uveitis during Pregnancy","volume":"32","author":"L A Grotting","year":"2017","journal-title":"Semin Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3389\/fphar.2020.00655","article-title":"New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview","volume":"11","author":"R A Valenzuela","year":"2020","journal-title":"Front Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3109\/09273948.2015.1099680","article-title":"Tocilizumab in Uveitic Macular Edema Refractory to Previous Immunomodulatory Treatment","volume":"25","author":"C ME Deuter","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1916.e1","DOI":"10.1016\/j.ophtha.2005.06.009","article-title":"Outcome of intravitreal triamcinolone in uveitis","volume":"112","author":"H Kok","year":"2005","journal-title":"Ophthalmology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"4864","DOI":"10.1167\/iovs.12-10981","article-title":"Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterior uveitis","volume":"54","author":"S Lightman","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1080\/09273948.2017.1294185","article-title":"Clinical Outcomes of Intravitreal Preservative-Free Triamcinolone Preparation (Triesence\u00ae) for Cystoid Macular Oedema and Inflammation in Patients with Uveitis","volume":"26","author":"L R Steeples","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.ophtha.2006.02.021","article-title":"Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study","volume":"113","author":"G J Jaffe","year":"2006","journal-title":"Ophthalmology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1001\/archophthalmol.2010.339","article-title":"Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis","volume":"129","author":"C Lowder","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"343","DOI":"10.4155\/tde-2019-0024","article-title":"Dexamethasone intravitreal implant (OZURDEX\u00ae) for macular edema secondary to noninfectious uveitis: a review of the literature","volume":"10","author":"H Massa","year":"2019","journal-title":"Ther Deliv"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s40265-020-01314-y","article-title":"Uveitis Therapy: The Corticosteroid Options","volume":"80","author":"L M Valdes","year":"2020","journal-title":"Drugs"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.ophtha.2012.04.030","article-title":"Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema","volume":"119","author":"P A Campochiaro","year":"2012","journal-title":"Ophthalmology"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ajo.2005.08.025","article-title":"Research criteria for the diagnosis of birdshot chorioretinopathy: results of an international consensus conference","volume":"141","author":"R D Levinson","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ajo.2021.03.059","article-title":"Classification Criteria for Birdshot Chorioretinitis","volume":"228","author":"Standardization of Uveitis Nomenclature (SUN) Working Group","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"ref28","first-page":"1078","article-title":"Criteria for diagnosis of Behcet\u02bcs disease. International Study Group for Behcet\u02bcs Disease","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The International Criteria for Behcet\u02bcs Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","author":"International Team for the Revision of the International Criteria for Behcet\u02bcs Disease (ITR-ICBD)","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/s0002-9394(01)00925-4","article-title":"Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature","volume":"131","author":"R W Read","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12348-020-00214-2","article-title":"Initial-onset acute and chronic recurrent stages are two distinctive courses of Vogt-Koyanagi-Harada disease","volume":"10","author":"C A Urzua","year":"2020","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/s0161-6420(85)34001-0","article-title":"Standardization of vitreal inflammatory activity in intermediate and posterior uveitis","volume":"92","author":"R B Nussenblatt","year":"1985","journal-title":"Ophthalmology"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Behcet\u02bcs syndrome","volume":"77","author":"G Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1136\/ard.60.1.83","article-title":"HHV8 associated Kaposi\u02bcs sarcoma during triple immunosuppressive treatment with cyclosporin A, azathioprine, and prednisolone for ocular Behcet\u02bcs disease and complete remission of both disorders with interferon alpha","volume":"60","author":"I Kotter","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"ref36","first-page":"225","article-title":"The eighth Frederick H. Verhoeff Lecture. presented by saiichi mishima, MD Behcet\u02bcs disease in Japan: ophthalmologic aspects","volume":"77","author":"S Mishima","year":"1979","journal-title":"Trans Am Ophthalmol Soc"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1136\/bjo.70.8.589","article-title":"Treatment and visual prognosis in Behcet\u02bcs disease","volume":"70","author":"D Benezra","year":"1986","journal-title":"Br J Ophthalmol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.ophtha.2003.09.031","article-title":"Birdshot chorioretinopathy: long-term manifestations and visual prognosis","volume":"111","author":"A Rothova","year":"2004","journal-title":"Ophthalmology"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/00055735-200012000-00009","article-title":"Vogt-Koyanagi-Harada disease","volume":"11","author":"R W Read","year":"2000","journal-title":"Curr Opin Ophthalmol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/APO.0b013e31826f68a1","article-title":"Clinical Features, Investigations, Management, and Prognosis of Serpiginous Choroiditis","volume":"1","author":"R Annamalai","year":"2012","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.ajo.2004.01.053","article-title":"The white dot syndromes","volume":"137","author":"D A Quillen","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"105","DOI":"10.22336\/rjo.2018.16","article-title":"The use of biologic therapies in uveitis","volume":"62","author":"I Duica","year":"2018","journal-title":"Rom J Ophthalmol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2174\/1574886310666151014114925","article-title":"Biologic Therapy in Inflammatory Eye Conditions (Ophthalmology): Safety Profile","volume":"11","author":"P Neri","year":"2016","journal-title":"Curr Drug Saf"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.semarthrit.2019.06.004","article-title":"New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review","volume":"49","author":"J T Rosenbaum","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"377","DOI":"10.5414\/CP202171","article-title":"Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults","volume":"53","author":"J Borras-Blasco","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.17219\/acem\/125431","article-title":"Adalimumab in the treatment of non-infectious uveitis","volume":"29","author":"A Burek-Michalska","year":"2020","journal-title":"Adv Clin Exp Med"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/25785826.2019.1642080","article-title":"The effectiveness of adalimumab treatment for non-infectious uveitis","volume":"42","author":"E Hasegawa","year":"2019","journal-title":"Immunol Med"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/1744666X.2017.1288097","article-title":"Adalimumab for the treatment of uveitis","volume":"13","author":"K C LaMattina","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10067-019-04875-w","article-title":"JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis","volume":"39","author":"E Miserocchi","year":"2020","journal-title":"Clin Rheumatol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1080\/1744666X.2018.1504678","article-title":"Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors","volume":"14","author":"F Atzeni","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3390\/jfb6030650","article-title":"Intraocular Implants for the Treatment of Autoimmune Uveitis","volume":"6","author":"D J Lee","year":"2015","journal-title":"J Funct Biomater"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/14712598.2019.1595578","article-title":"Expert opinion on the use of biological therapy in non-infectious uveitis","volume":"19","author":"S Touhami","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1097\/IAE.0b013e31823496a3","article-title":"Effect of intravitreal methotrexate and aqueous humor cytokine levels in refractory retinal vasculitis in Behcet disease","volume":"32","author":"J H Bae","year":"2012","journal-title":"Retina"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1097\/ICO.0b013e3182910106","article-title":"Toxic corneal epitheliopathy after intravitreal methotrexate and its treatment with oral folic acid","volume":"32","author":"I Gorovoy","year":"2013","journal-title":"Cornea"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.ophtha.2008.10.033","article-title":"Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema","volume":"116","author":"S R Taylor","year":"2009","journal-title":"Ophthalmology"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1097\/IAE.0b013e31828ac07d","article-title":"Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis","volume":"33","author":"S RJ Taylor","year":"2013","journal-title":"Retina"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2147\/OPTH.S198401","article-title":"Outcomes of treatment with sirolimus for non-infectious uveitis: a meta-analysis and systematic review","volume":"13","author":"V LO Cabahug","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.3390\/jcm9082672","article-title":"Corneal Epithelial Toxicity after Intravitreal Methotrexate Injection for Vitreoretinal Lymphoma: Clinical and In Vitro Studies","volume":"9","author":"Y Jeong","year":"2020","journal-title":"J Clin Med"},{"key":"ref59","first-page":"611","article-title":"[A case of intraocular lymphoma having retinal adverse events associated with intravitreal methotrexate]","volume":"115","author":"N Kuroiwa","year":"2011","journal-title":"Nihon Ganka Gakkai Zasshi"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12886-020-01464-3","article-title":"Reduced frequency of Intravitreal methotrexate injection lowers the risk of Keratopathy in Vitreoretinal lymphoma patients","volume":"20","author":"X Zhou","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.oret.2017.08.015","article-title":"Treatment of Geographic Atrophy with Intravitreal Sirolimus: The Age-Related Eye Disease Study 2 Ancillary Study","volume":"2","author":"G Gensler","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.ophtha.2020.03.033","article-title":"Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: Results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program","volume":"127","author":"P T Merrill","year":"2020","journal-title":"Ophthalmology"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/IAE.0b013e3181bcef3b","article-title":"Adverse events after intravitreal infliximab (Remicade)","volume":"30","author":"M Giganti","year":"2010","journal-title":"Retina"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1097\/IAE.0000000000001109","article-title":"Intravitreal infliximab in refractory uveitis in Behcet\u02bcs disease: A safety and efficacy clinical study","volume":"36","author":"M ME Hamza","year":"2016","journal-title":"Retina"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3109\/09273948.2014.990041","article-title":"Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study","volume":"24","author":"R N Hamam","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"e665","DOI":"10.1111\/aos.13699","article-title":"Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis \u2013 a systematic review","volume":"96","author":"I Leal","year":"2018","journal-title":"Acta Ophthalmol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s00417-005-0109-1","article-title":"Intravitreal implantation of the biodegradable cyclosporin A drug delivery system for experimental chronic uveitis","volume":"244","author":"X Dong","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1021\/acs.molpharmaceut.8b00014","article-title":"Cyclosporine A-Loaded Nanocarriers for Topical Treatment of Murine Experimental Autoimmune Uveoretinitis","volume":"15","author":"M Kasper","year":"2018","journal-title":"Mol Pharm"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1002\/jps.24385","article-title":"Preparation and in vitro\/in vivo evaluation of cyclosporin A-loaded nanodecorated ocular implants for subconjunctival application","volume":"104","author":"S B Pehlivan","year":"2015","journal-title":"J Pharm Sci"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"118573","DOI":"10.1016\/j.ijpharm.2019.118573","article-title":"Treatment of endotoxin-induced uveitis by topical application of cyclosporine a-loaded PolyGel in rabbit eyes","volume":"569","author":"A Alshamsan","year":"2019","journal-title":"Int J Pharm"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.mehy.2013.08.007","article-title":"Topical tacrolimus nanoemulsion, a promising therapeutic approach for uveitis","volume":"81","author":"V Garg","year":"2013","journal-title":"Med Hypotheses"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.xphs.2020.10.060","article-title":"Amelioration of Endotoxin-Induced Uveitis in Rabbit by Topical Administration of Tacrolimus Proglycosome Nano-Vesicles","volume":"110","author":"V Garg","year":"2021","journal-title":"J Pharm Sci"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.exer.2018.01.003","article-title":"Novel everolimus-loaded nanocarriers for topical treatment of murine experimental autoimmune uveoretinitis (EAU)","volume":"168","author":"M Kasper","year":"2018","journal-title":"Exp Eye Res"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"376","DOI":"10.4103\/0301-4738.185605","article-title":"The efficacy of intravitreal interferon alpha-2b for the treatment of experimental endotoxin-induced uveitis","volume":"64","author":"M Afarid","year":"2016","journal-title":"Indian J Ophthalmol"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1097\/IAE.0b013e3181d3758a","article-title":"Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis","volume":"30","author":"M Farvardin","year":"2010","journal-title":"Retina"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1089\/jop.2011.0199","article-title":"Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis","volume":"28","author":"M Farvardin","year":"2012","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1080\/15569527.2019.1632883","article-title":"The efficacy of systemic and intravitreal infliximab treatments in an endotoxin-induced uveitis model","volume":"38","author":"O Donmez","year":"2019","journal-title":"Cutan Ocul Toxicol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1177\/112067210901900521","article-title":"Intravitreal infliximab in experimental endotoxin-induced uveitis","volume":"19","author":"H Hosseini","year":"2009","journal-title":"Eur J Ophthalmol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1089\/jop.2012.0238","article-title":"Comparison of acute effect of systemic versus intravitreal infliximab treatment in an experimental model of endotoxin-induced uveitis","volume":"30","author":"E Yuksel","year":"2014","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1136\/bjophthalmol-2016-310044","article-title":"Treatment of experimental autoimmune uveoretinitis with intravitreal injection of infliximab encapsulated in liposomes","volume":"101","author":"R Zhang","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"117216","DOI":"10.1016\/j.carbpol.2020.117216","article-title":"Hydrogel eye drops as a non-invasive drug carrier for topical enhanced Adalimumab permeation and highly efficient uveitis treatment","volume":"253","author":"Z Chen","year":"2021","journal-title":"Carbohydr Polym"}],"container-title":["Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2074-9102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T23:57:47Z","timestamp":1733443067000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2074-9102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":80,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,5]]},"published-print":{"date-parts":[[2024,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2074-9102","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0023-2165","1439-3999"],"issn-type":[{"type":"print","value":"0023-2165"},{"type":"electronic","value":"1439-3999"}],"subject":[],"published":{"date-parts":[[2023,7,12]]}}}